Updates in the Management of Tumor Lysis Syndrome

TLS is a potentially serious complication of anticancer therapy. If left untreated, its progression may cause acute kidney failure, cardiac arrhythmias, seizures, loss of muscle control, and death. TLS can be managed effectively if it is recognized early and preventative measures instituted prior to the initiation of anticancer therapy. Identification of patients at higher risk for developing TLS, careful monitoring for any signs and symptoms, and implementation of adequate prophylactic measures are essential to avoid the fatal consequences of TLS. The risk of developing TLS persists even in the era of targeted therapies. A better understanding of the prevalence and management of TLS associated with targeted therapies is helpful to integrate appropriate supportive care measures into the management of patients with hematologic malignancies. Nurses require ongoing education that provides expert guidance for the optimal management of TLS in patients with hematologic malignancies.

Target Audience

This educational program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.
 

Learning Objectives

Following this activity, participants should be able to: 

  • Identify the risk factors associated with the development of TLS.
  • Outline the indications for anti-hyperuricemic agents used for the management of TLS.
  • Develop strategies for the management of TLS based on risk assessment, underlying malignancy and type of therapy administered.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Celgene Corporation
  • Coherus Biosciences
  • Genentech
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 0.73 ANCC contact hours
  • 0.73 Participation
  • 0.73 Nurse
Course opens: 
11/01/2019
Course expires: 
10/31/2020
Cost:
$0.00

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
UCSF Helen Diller Family Comprehensive Cancer Center

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Salix Pharmaceuticals: Consulting Fee
Stemline Therapeutics: Consulting Fee

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; Kathy Ann Smith, CHCP; Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Mary A. Dwyer, MS, CGC; Alyse Johnson-Chilla, MS; Rashmi Kumar, PhD; Hema Sundar, PhD

The NCCN Clinical staff listed below discloses the following relevant financial relationships:

Griselda Zuccarino-Catania, PhD
Janssen Pharmaceutica Products, LP: Salary (Spouse)

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of 0.73 contact hours.

Available Credit

  • 0.73 ANCC contact hours
  • 0.73 Participation
  • 0.73 Nurse

Accreditation Period

Course opens: 
11/01/2019
Course expires: 
10/31/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: